Evidence — Selank
peptide · asset evidence level: emerging
Evidence quality breakdown (linked documents)
expert_opinion: 12clinical: 1
Linked source documents (13)
- TA1 — Peptide Dosing Protocols reference (patient_education · expert_opinion)
- Semax — Peptide Dosing Protocols reference (patient_education · expert_opinion)
- Selank — Peptide Dosing Protocols reference (patient_education · expert_opinion)
- PT-141 — Peptide Dosing Protocols reference (patient_education · expert_opinion)
- Oxytocin Acetate — Peptide Dosing Protocols reference (patient_education · expert_opinion)
- Ipamorelin — Peptide Dosing Protocols reference (patient_education · expert_opinion)
- DSIP — Peptide Dosing Protocols reference (patient_education · expert_opinion)
- Oxytocin Acetate — Peptide Protocol Wiki reference (patient_education · expert_opinion)
- SS-31 — Peptide Protocol Wiki reference (patient_education · expert_opinion)
- Semax — Peptide Protocol Wiki reference (patient_education · expert_opinion)
- Selank — Peptide Protocol Wiki reference (patient_education · expert_opinion)
- DSIP — Peptide Protocol Wiki reference (patient_education · expert_opinion)
- Selank: Mechanistic Overview (internal_protocol · clinical)
Provider dosing references (Stage 9, source-attributed)
250-500 mcg intranasally daily (or 0.15% solution per protocol) — Practitioner Peptide Dosing Reference (commonly published ranges)
300-600 mcg per dose intranasal; 200-400 mcg per dose subcutaneous — Peptide Protocol Wiki (peptideprotocolwiki.com)
Standard: 250-500 mcg per day · Low: 250 mcg · High: 500 mcg — Peptide Dosing Protocols (peptidedosingprotocols.com)
Dosing claims (114) · Safety claims (39)
Extracted claims are provider-review scaffolding, stored verbatim with source attribution — not recommendations or dosing guidance.